Full history for every metric is available with a Kvantra account
IntelGenx Technologies Corp. (IGX.TO)
Key financial summary
Financials in USD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 2 | 1 | 2 | 2 | 1 | 1 | 1 |
| Operating profit | $m | -9 | -10 | |||||
| Net profit | $m | -10 | -11 | -7 | -9 | -11 | -10 | -11 |
| EPS reported | $ | -0.06 | -0.06 | |||||
| Operating cashflow per share | $ | -0.04 | -0.04 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -0.04 | -0.04 | |||||
| Free cash flow | $m | -7 | -7 | |||||
| Net debt | $m | 13 | 15 | |||||
| Book value equity | $m | -12 | -15 | |||||
| Book value per share | $ | -0.07 | -0.09 | |||||
| Number of shares | m | 174.65 | 174.66 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | -1.83 | -1.91 | |||||
| P/S LTM | x | 21.54 | 27.99 | |||||
| P/FCF LTM | x | -3.34 | -4.07 | |||||
| EV/EBITDA LTM | x | -4.72 | -5.47 | |||||
| EV/Sales LTM | x | 34.27 | 42.43 | |||||
| Earnings Yield LTM | % | -44.35% | -33.76% | |||||
| FCF Yield | % | -29.95% | -24.56% | |||||
| Quality | ||||||||
| ROE | % | 81.06% | 126.70% | |||||
| ROIC | % | -291.67% | -291.67% | |||||
| Operating margin | % | -913.47% | -913.47% | |||||
| Gross margin | % | -66.79% | -66.79% | |||||
| FCF/Sales | % | -645.33% | -645.33% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +9.37% | +20.11% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -0.43 | -0.44 | |||||
| Net Debt/EBITDA | x | -1.75 | -1.75 | |||||
| EBIT/Net interest | x | -5.84 | -5.84 | |||||
| Net debt/market cap | % | 59.05% | 51.55% | |||||
| Net debt/Equity | x | -1.08 | -0.99 | |||||
| Gross debt/equity | x | -1.27 | -1.07 | |||||
Company overview
IntelGenx Technologies Corp. is a pharmaceutical drug delivery enterprise focused on the creation and manufacturing of advanced oral thin film products. The company's diverse product pipeline encompasses various oral film formulations designed to address a wide spectrum of medical conditions. These include INT0008/2008, a Rizatriptan film for migraine management; INT0046/2018 for adult applications; INT0007/2006, an oral film targeting erectile dysfunction; INT0043/2015, a montelukast-based film for Alzheimer's disease; INT0027/2011, intended for opioid addiction treatment; INT0010/2006, addressing neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, formulated for schizophrenia or bipolar I disorder; and INT0048/2020, developed for veterinary health. Additionally, IntelGenx is actively developing other candidates identified as INT0039/2013, INT0040/2014, INT0052/2020, INT0053/2020, and INT0054/2020. The company has established strategic partnerships, including a comprehensive licensing, development, and supply agreement with Tilray, Inc., alongside a development pact with Cynapsus Therapeutics Inc. Founded in 2003, IntelGenx Technologies Corp. is headquartered in Montreal, Canada.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
IntelGenx Technologies Corp. (IGX.TO)
IntelGenx Technologies Corp. is a pharmaceutical drug delivery enterprise focused on the creation and manufacturing of advanced oral thin film products. The company's diverse product pipeline encompasses various oral film formulations designed to address a wide spectrum of medical conditions. These include INT0008/2008, a Rizatriptan film for migraine management; INT0046/2018 for adult applications; INT0007/2006, an oral film targeting erectile dysfunction; INT0043/2015, a montelukast-based film for Alzheimer's disease; INT0027/2011, intended for opioid addiction treatment; INT0010/2006, addressing neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, formulated for schizophrenia or bipolar I disorder; and INT0048/2020, developed for veterinary health. Additionally, IntelGenx is actively developing other candidates identified as INT0039/2013, INT0040/2014, INT0052/2020, INT0053/2020, and INT0054/2020. The company has established strategic partnerships, including a comprehensive licensing, development, and supply agreement with Tilray, Inc., alongside a development pact with Cynapsus Therapeutics Inc. Founded in 2003, IntelGenx Technologies Corp. is headquartered in Montreal, Canada.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free